Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y, Liu J, Jaime-Ramirez AC, Hong B, Geng F, Guo D, Bystry D, Phelphs M, Quadri H, Lee TJ, Kaur B.
Yoo JY, et al. Among authors: liu j.
Neuro Oncol. 2019 Sep 6;21(9):1131-1140. doi: 10.1093/neuonc/noz079.
Neuro Oncol. 2019.
PMID: 31063549
Free PMC article.